<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39204073</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">950</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12080950</ELocationID><Abstract><AbstractText>With the continuous advancements in tumor immunotherapy, researchers are actively exploring new treatment methods. Peptide therapeutic cancer vaccines have garnered significant attention for their potential in improving patient outcomes. Despite its potential, only a single peptide-based cancer vaccine has been approved by the U.S. Food and Drug Administration (FDA). A comprehensive understanding of the underlying mechanisms and current development status is crucial for advancing these vaccines. This review provides an in-depth analysis of the production principles and therapeutic mechanisms of peptide-based cancer vaccines, highlights the commonly used peptide-based cancer vaccines, and examines the synergistic effects of combining these vaccines with immunotherapy, targeted therapy, radiotherapy, and chemotherapy. While some studies have yielded suboptimal results, the potential of combination therapies remains substantial. Additionally, we addressed the management and adverse events associated with peptide-based cancer vaccines, noting their relatively higher safety profile compared to traditional radiotherapy and chemotherapy. Lastly, we also discussed the roles of adjuvants and targeted delivery systems in enhancing vaccine efficacy. In conclusion, this review comprehensively outlines the current landscape of peptide-based cancer vaccination and underscores its potential as a pivotal immunotherapy approach.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dequan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0003-1242-8792</Identifier><AffiliationInfo><Affiliation>Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinghan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Stomatology, General Hospital of Northern Theater Command, Shenyang 110016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shijin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0006-1140-9858</Identifier><AffiliationInfo><Affiliation>Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Guangzhen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Che</LastName><ForeName>Xiangyu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-4646-1390</Identifier><AffiliationInfo><Affiliation>Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No.2022CR015</GrantID><Agency>the Horizontal Project Department Fund of the First Affiliated Hospital of Dalian Medical University</Agency><Country /></Grant><Grant><GrantID>No.JYTMS20230577</GrantID><Agency>the Liaoning Provincial Education Department</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adjuvants</Keyword><Keyword MajorTopicYN="N">combination therapy</Keyword><Keyword MajorTopicYN="N">delivery systems</Keyword><Keyword MajorTopicYN="N">mechanism of action</Keyword><Keyword MajorTopicYN="N">medication administration</Keyword><Keyword MajorTopicYN="N">peptide-based cancer vaccines</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39204073</ArticleId><ArticleId IdType="pmc">PMC11359700</ArticleId><ArticleId IdType="doi">10.3390/vaccines12080950</ArticleId><ArticleId IdType="pii">vaccines12080950</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Decker W.K., Safdar A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley’s legacy revisited. Cytokine Growth Factor Rev. 2009;20:271–281. doi: 10.1016/j.cytogfr.2009.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2009.07.004</ArticleId><ArticleId IdType="pubmed">19656718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoption Cann S.A., van Netten J.P., van Netten C. Dr William Coley and tumour regression: A place in history or in the future. Postgrad. Med. J. 2003;79:672–680. doi: 10.1093/postgradmedj/79.938.672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/postgradmedj/79.938.672</ArticleId><ArticleId IdType="pmc">PMC1742910</ArticleId><ArticleId IdType="pubmed">14707241</ArticleId></ArticleIdList></Reference><Reference><Citation>Coley W.B. The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus) Proc. R. Soc. Med. 1910;3:1–48. doi: 10.1177/003591571000301601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/003591571000301601</ArticleId><ArticleId IdType="pmc">PMC1961042</ArticleId><ArticleId IdType="pubmed">19974799</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647. doi: 10.1126/science.1840703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1840703</ArticleId><ArticleId IdType="pubmed">1840703</ArticleId></ArticleIdList></Reference><Reference><Citation>Boon T., Old L.J. Cancer Tumor antigens. Curr. Opin. Immunol. 1997;9:681–683. doi: 10.1016/S0952-7915(97)80049-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0952-7915(97)80049-0</ArticleId><ArticleId IdType="pubmed">9438857</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnet F.M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 1970;13:1–27. doi: 10.1159/000386035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000386035</ArticleId><ArticleId IdType="pubmed">4921480</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas L. On immunosurveillance in human cancer. Yale J. Biol. Med. 1982;55:329–333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2596448</ArticleId><ArticleId IdType="pubmed">6758376</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D.S., Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330. doi: 10.1038/nature21349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21349</ArticleId><ArticleId IdType="pubmed">28102259</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Tang H., Li L., Wang X., Yu Z., Li J. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif. 2021;54:e13025. doi: 10.1111/cpr.13025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpr.13025</ArticleId><ArticleId IdType="pmc">PMC8088465</ArticleId><ArticleId IdType="pubmed">33754407</ArticleId></ArticleIdList></Reference><Reference><Citation>Melief C.J., van Hall T., Arens R., Ossendorp F., van der Burg S.H. Therapeutic cancer vaccines. J. Clin. Investig. 2015;125:3401–3412. doi: 10.1172/JCI80009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI80009</ArticleId><ArticleId IdType="pmc">PMC4588240</ArticleId><ArticleId IdType="pubmed">26214521</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield L.H. Cancer vaccines. BMJ. 2015;350:h988. doi: 10.1136/bmj.h988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h988</ArticleId><ArticleId IdType="pmc">PMC4707521</ArticleId><ArticleId IdType="pubmed">25904595</ArticleId></ArticleIdList></Reference><Reference><Citation>Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39:38–48. doi: 10.1016/j.immuni.2013.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.07.004</ArticleId><ArticleId IdType="pmc">PMC3788678</ArticleId><ArticleId IdType="pubmed">23890062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Chakraborty N.G., Sporn J.R., Kurtzman S.H., Ergin M.T., Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 1996;56:2479–2483.</Citation><ArticleIdList><ArticleId IdType="pubmed">8653680</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeurer M.J., Storkus W.J., Kirkwood J.M., Lotze M.T. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 1996;6:11–24. doi: 10.1097/00008390-199602000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00008390-199602000-00003</ArticleId><ArticleId IdType="pubmed">8640065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., Yamase H., Sporn J.R., Kurtzman S.K., Ergin M.T., Ozols J., Meehan J., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA. 1995;92:8078–8082. doi: 10.1073/pnas.92.17.8078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.17.8078</ArticleId><ArticleId IdType="pmc">PMC41290</ArticleId><ArticleId IdType="pubmed">7644541</ArticleId></ArticleIdList></Reference><Reference><Citation>Biri-Kovács B., Bánóczi Z., Tummalapally A., Szabó I. Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy. Pharmaceutics. 2023;15:452. doi: 10.3390/pharmaceutics15020452.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15020452</ArticleId><ArticleId IdType="pmc">PMC9963291</ArticleId><ArticleId IdType="pubmed">36839774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott P.A., Hu Z., Keskin D.B., Shukla S.A., Sun J., Bozym D.J., Zhang W., Luoma A., Giobbie-Hurder A., Peter L., et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217–221. doi: 10.1038/nature22991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22991</ArticleId><ArticleId IdType="pmc">PMC5577644</ArticleId><ArticleId IdType="pubmed">28678778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012;12:252–264. doi: 10.1038/nrc3239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3239</ArticleId><ArticleId IdType="pmc">PMC4856023</ArticleId><ArticleId IdType="pubmed">22437870</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlom J., Arlen P.M., Gulley J.L. Cancer vaccines: Moving beyond current paradigms. Clin. Cancer Res. 2007;13:3776–3782. doi: 10.1158/1078-0432.CCR-07-0588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-07-0588</ArticleId><ArticleId IdType="pmc">PMC2536755</ArticleId><ArticleId IdType="pubmed">17606707</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010;363:411–422. doi: 10.1056/NEJMoa1001294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1001294</ArticleId><ArticleId IdType="pubmed">20818862</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., Gailani F., Riley L., Conlon K., Pockaj B., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011;364:2119–2127. doi: 10.1056/NEJMoa1012863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1012863</ArticleId><ArticleId IdType="pmc">PMC3517182</ArticleId><ArticleId IdType="pubmed">21631324</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoen R.E., Boardman L.A., Cruz-Correa M., Bansal A., Kastenberg D., Hur C., Dzubinski L., Kaufman S.F., Rodriguez L.M., Richmond E., et al. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma. Clin. Cancer Res. 2023;29:1678–1688. doi: 10.1158/1078-0432.CCR-22-3168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-22-3168</ArticleId><ArticleId IdType="pmc">PMC10159922</ArticleId><ArticleId IdType="pubmed">36892581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S.Y., Yu K.D. Breast Cancer Vaccines: Disappointing or Promising? Front. Immunol. 2022;13:828386. doi: 10.3389/fimmu.2022.828386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.828386</ArticleId><ArticleId IdType="pmc">PMC8831788</ArticleId><ArticleId IdType="pubmed">35154149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahedipour F., Jamialahmadi K., Zamani P., Reza Jaafari M. Improving the efficacy of peptide vaccines in cancer immunotherapy. Int. Immunopharmacol. 2023;123:110721. doi: 10.1016/j.intimp.2023.110721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110721</ArticleId><ArticleId IdType="pubmed">37543011</ArticleId></ArticleIdList></Reference><Reference><Citation>Klausen U., Holmberg S., Holmström M.O., Jørgensen N.G.D., Grauslund J.H., Svane I.M., Andersen M.H. Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. Front. Immunol. 2018;9:2264. doi: 10.3389/fimmu.2018.02264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02264</ArticleId><ArticleId IdType="pmc">PMC6174926</ArticleId><ArticleId IdType="pubmed">30327655</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2015;372:2521–2532. doi: 10.1056/NEJMoa1503093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1503093</ArticleId><ArticleId IdType="pubmed">25891173</ArticleId></ArticleIdList></Reference><Reference><Citation>Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S., Tykodi S.S., Sosman J.A., Procopio G., Plimack E.R., et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2015;373:1803–1813. doi: 10.1056/NEJMoa1510665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1510665</ArticleId><ArticleId IdType="pmc">PMC5719487</ArticleId><ArticleId IdType="pubmed">26406148</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer J., Reckamp K.L., Baas P., Crinò L., Eberhardt W.E., Poddubskaya E., Antonia S., Pluzanski A., Vokes E.E., Holgado E., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015;373:123–135. doi: 10.1056/NEJMoa1504627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504627</ArticleId><ArticleId IdType="pmc">PMC4681400</ArticleId><ArticleId IdType="pubmed">26028407</ArticleId></ArticleIdList></Reference><Reference><Citation>Plosker G.L. Sipuleucel-T: In metastatic castration-resistant prostate cancer. Drugs. 2011;71:101–108. doi: 10.2165/11206840-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11206840-000000000-00000</ArticleId><ArticleId IdType="pubmed">21175243</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: Putting innate immunity to work. Immunity. 2010;33:492–503. doi: 10.1016/j.immuni.2010.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.10.002</ArticleId><ArticleId IdType="pmc">PMC3420356</ArticleId><ArticleId IdType="pubmed">21029960</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004;10:909–915. doi: 10.1038/nm1100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1100</ArticleId><ArticleId IdType="pmc">PMC1435696</ArticleId><ArticleId IdType="pubmed">15340416</ArticleId></ArticleIdList></Reference><Reference><Citation>Pol J., Bloy N., Buqué A., Eggermont A., Cremer I., Sautès-Fridman C., Galon J., Tartour E., Zitvogel L., Kroemer G., et al. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology. 2015;4:e974411. doi: 10.4161/2162402X.2014.974411.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/2162402X.2014.974411</ArticleId><ArticleId IdType="pmc">PMC4485775</ArticleId><ArticleId IdType="pubmed">26137405</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo Tardón M., Allard M., Dutoit V., Dietrich P.Y., Walker P.R. Peptides as cancer vaccines. Curr. Opin. Pharmacol. 2019;47:20–26. doi: 10.1016/j.coph.2019.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2019.01.007</ArticleId><ArticleId IdType="pubmed">30831470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezu L., Kepp O., Cerrato G., Pol J., Fucikova J., Spisek R., Zitvogel L., Kroemer G., Galluzzi L. Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology. 2018;7:e1511506. doi: 10.1080/2162402X.2018.1511506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2018.1511506</ArticleId><ArticleId IdType="pmc">PMC6279318</ArticleId><ArticleId IdType="pubmed">30524907</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemesh C.S., Hsu J.C., Hosseini I., Shen B.Q., Rotte A., Twomey P., Girish S., Wu B. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Mol. Ther. 2021;29:555–570. doi: 10.1016/j.ymthe.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7854282</ArticleId><ArticleId IdType="pubmed">33038322</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K., Yamada A. Personalized peptide vaccines: A new therapeutic modality for cancer. Cancer Sci. 2006;97:970–976. doi: 10.1111/j.1349-7006.2006.00272.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2006.00272.x</ArticleId><ArticleId IdType="pmc">PMC11158045</ArticleId><ArticleId IdType="pubmed">16984371</ArticleId></ArticleIdList></Reference><Reference><Citation>Slingluff C.L., Jr. The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination? Cancer J. 2011;17:343–350. doi: 10.1097/PPO.0b013e318233e5b2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PPO.0b013e318233e5b2</ArticleId><ArticleId IdType="pmc">PMC3204371</ArticleId><ArticleId IdType="pubmed">21952285</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelde A., Rammensee H.G., Walz J.S. The Peptide Vaccine of the Future. Mol. Cell Proteom. 2021;20:100022. doi: 10.1074/mcp.R120.002309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.R120.002309</ArticleId><ArticleId IdType="pmc">PMC7950068</ArticleId><ArticleId IdType="pubmed">33583769</ArticleId></ArticleIdList></Reference><Reference><Citation>Skwarczynski M., Toth I. Peptide-based synthetic vaccines. Chem. Sci. 2016;7:842–854. doi: 10.1039/C5SC03892H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5SC03892H</ArticleId><ArticleId IdType="pmc">PMC5529997</ArticleId><ArticleId IdType="pubmed">28791117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaczmarek M., Poznańska J., Fechner F., Michalska N., Paszkowska S., Napierała A., Mackiewicz A. Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. Cells. 2023;12:2159. doi: 10.3390/cells12172159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12172159</ArticleId><ArticleId IdType="pmc">PMC10486481</ArticleId><ArticleId IdType="pubmed">37681891</ArticleId></ArticleIdList></Reference><Reference><Citation>Paston S.J., Brentville V.A., Symonds P., Durrant L.G. Cancer Vaccines, Adjuvants, and Delivery Systems. Front. Immunol. 2021;12:627932. doi: 10.3389/fimmu.2021.627932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.627932</ArticleId><ArticleId IdType="pmc">PMC8042385</ArticleId><ArticleId IdType="pubmed">33859638</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong H., Overwijk W.W. Adjuvants for peptide-based cancer vaccines. J. Immunother. Cancer. 2016;4:56. doi: 10.1186/s40425-016-0160-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-016-0160-y</ArticleId><ArticleId IdType="pmc">PMC5028954</ArticleId><ArticleId IdType="pubmed">27660710</ArticleId></ArticleIdList></Reference><Reference><Citation>Backlund C.M., Holden R.L., Moynihan K.D., Garafola D., Farquhar C., Mehta N.K., Maiorino L., Pham S., Iorgulescu J.B., Reardon D.A., et al. Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc. Natl. Acad. Sci. USA. 2022;119:e2204078119. doi: 10.1073/pnas.2204078119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2204078119</ArticleId><ArticleId IdType="pmc">PMC9371699</ArticleId><ArticleId IdType="pubmed">35914154</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldaver D., Larché M. Immunotherapy with peptides. Allergy. 2011;66:784–791. doi: 10.1111/j.1398-9995.2011.02610.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1398-9995.2011.02610.x</ArticleId><ArticleId IdType="pubmed">21507007</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmiani G., Russo V., Maccalli C., Parolini D., Rizzo N., Maio M. Peptide-based vaccines for cancer therapy. Hum. Vaccin. Immunother. 2014;10:3175–3178. doi: 10.4161/hv.29418.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.29418</ArticleId><ArticleId IdType="pmc">PMC4514143</ArticleId><ArticleId IdType="pubmed">25483658</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher E., Pavlenko K., Vlasov A., Ramenskaya G. Peptide-Based Therapeutics for Oncology. Pharmaceut. Med. 2019;33:9–20. doi: 10.1007/s40290-018-0261-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40290-018-0261-7</ArticleId><ArticleId IdType="pubmed">31933267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.F., Gully B.S., Gras S., Beringer D.X., Kjer-Nielsen L., Cebon J., McCluskey J., Chen W., Rossjohn J. Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. Nat. Commun. 2018;9:1026. doi: 10.1038/s41467-018-03321-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03321-w</ArticleId><ArticleId IdType="pmc">PMC5847591</ArticleId><ArticleId IdType="pubmed">29531227</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng M., Mo Y., Wang Y., Wu P., Zhang Y., Xiong F., Guo C., Wu X., Li Y., Li X., et al. Neoantigen vaccine: An emerging tumor immunotherapy. Mol. Cancer. 2019;18:128. doi: 10.1186/s12943-019-1055-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-019-1055-6</ArticleId><ArticleId IdType="pmc">PMC6708248</ArticleId><ArticleId IdType="pubmed">31443694</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd-Aziz N., Poh C.L. Development of Peptide-Based Vaccines for Cancer. J. Oncol. 2022;2022:9749363. doi: 10.1155/2022/9749363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9749363</ArticleId><ArticleId IdType="pmc">PMC8941562</ArticleId><ArticleId IdType="pubmed">35342400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T., Egawa S., Uemura H. Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat. Rev. Urol. 2017;14:501–510. doi: 10.1038/nrurol.2017.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2017.77</ArticleId><ArticleId IdType="pubmed">28561807</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobuoka D., Yoshikawa T., Fujiwara T., Nakatsura T. Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy. Hum. Vaccin. Immunother. 2013;9:1234–1236. doi: 10.4161/hv.23990.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.23990</ArticleId><ArticleId IdType="pmc">PMC3901811</ArticleId><ArticleId IdType="pubmed">23411443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav M., Jhunjhunwala S., Phung Q.T., Lupardus P., Tanguay J., Bumbaca S., Franci C., Cheung T.K., Fritsche J., Weinschenk T., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572–576. doi: 10.1038/nature14001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14001</ArticleId><ArticleId IdType="pubmed">25428506</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassani-Sternberg M., Bräunlein E., Klar R., Engleitner T., Sinitcyn P., Audehm S., Straub M., Weber J., Slotta-Huspenina J., Specht K., et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 2016;7:13404. doi: 10.1038/ncomms13404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13404</ArticleId><ArticleId IdType="pmc">PMC5121339</ArticleId><ArticleId IdType="pubmed">27869121</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal N.H., Parsons D.W., Peggs K.S., Velculescu V., Kinzler K.W., Vogelstein B., Allison J.P. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008;68:889–892. doi: 10.1158/0008-5472.CAN-07-3095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-3095</ArticleId><ArticleId IdType="pubmed">18245491</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasagi M., Shukla S.A., Fritsch E.F., Keskin D.B., DeLuca D., Carmona E., Zhang W., Sougnez C., Cibulskis K., Sidney J., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124:453–462. doi: 10.1182/blood-2014-04-567933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-04-567933</ArticleId><ArticleId IdType="pmc">PMC4102716</ArticleId><ArticleId IdType="pubmed">24891321</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn O.J. Cancer immunology. N. Engl. J. Med. 2008;358:2704–2715. doi: 10.1056/NEJMra072739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra072739</ArticleId><ArticleId IdType="pubmed">18565863</ArticleId></ArticleIdList></Reference><Reference><Citation>Scanlan M.J., Simpson A.J., Old L.J. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun. 2004;4:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">14738373</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74. doi: 10.1126/science.aaa4971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa4971</ArticleId><ArticleId IdType="pubmed">25838375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128. doi: 10.1126/science.aaa1348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa1348</ArticleId><ArticleId IdType="pmc">PMC4993154</ArticleId><ArticleId IdType="pubmed">25765070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoof I., Peters B., Sidney J., Pedersen L.E., Sette A., Lund O., Buus S., Nielsen M. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2009;61:1–13. doi: 10.1007/s00251-008-0341-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-008-0341-z</ArticleId><ArticleId IdType="pmc">PMC3319061</ArticleId><ArticleId IdType="pubmed">19002680</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenzer S., Peters B., Bulik S., Schoor O., Lemmel C., Schatz M.M., Kloetzel P.M., Rammensee H.G., Schild H., Holzhütter H.G. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci. 2005;62:1025–1037. doi: 10.1007/s00018-005-4528-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-005-4528-2</ArticleId><ArticleId IdType="pubmed">15868101</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen M., Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 2016;8:33. doi: 10.1186/s13073-016-0288-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-016-0288-x</ArticleId><ArticleId IdType="pmc">PMC4812631</ArticleId><ArticleId IdType="pubmed">27029192</ArticleId></ArticleIdList></Reference><Reference><Citation>Jespersen M.C., Peters B., Nielsen M., Marcatili P. BepiPred-2.0: Improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45:W24–W29. doi: 10.1093/nar/gkx346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx346</ArticleId><ArticleId IdType="pmc">PMC5570230</ArticleId><ArticleId IdType="pubmed">28472356</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–581. doi: 10.1038/nature13988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13988</ArticleId><ArticleId IdType="pmc">PMC4279952</ArticleId><ArticleId IdType="pubmed">25428507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiter S., Vormehr M., van de Roemer N., Diken M., Löwer M., Diekmann J., Boegel S., Schrörs B., Vascotto F., Castle J.C., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520:692–696. doi: 10.1038/nature14426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14426</ArticleId><ArticleId IdType="pmc">PMC4838069</ArticleId><ArticleId IdType="pubmed">25901682</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., Lin J.C., Teer J.K., Cliften P., Tycksen E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013;19:747–752. doi: 10.1038/nm.3161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3161</ArticleId><ArticleId IdType="pmc">PMC3757932</ArticleId><ArticleId IdType="pubmed">23644516</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita R., Overton J.A., Greenbaum J.A., Ponomarenko J., Clark J.D., Cantrell J.R., Wheeler D.K., Gabbard J.L., Hix D., Sette A., et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2015;43:D405–D412. doi: 10.1093/nar/gku938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku938</ArticleId><ArticleId IdType="pmc">PMC4384014</ArticleId><ArticleId IdType="pubmed">25300482</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleri W., Vaughan K., Salimi N., Vita R., Peters B., Sette A. The Immune Epitope Database: How Data Are Entered and Retrieved. J. Immunol. Res. 2017;2017:5974574. doi: 10.1155/2017/5974574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/5974574</ArticleId><ArticleId IdType="pmc">PMC5467323</ArticleId><ArticleId IdType="pubmed">28634590</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskin D.B., Anandappa A.J., Sun J., Tirosh I., Mathewson N.D., Li S., Oliveira G., Giobbie-Hurder A., Felt K., Gjini E., et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565:234–239. doi: 10.1038/s41586-018-0792-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0792-9</ArticleId><ArticleId IdType="pmc">PMC6546179</ArticleId><ArticleId IdType="pubmed">30568305</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimawi M.F., Schiff R., Osborne C.K. Targeting HER2 for the treatment of breast cancer. Annu. Rev. Med. 2015;66:111–128. doi: 10.1146/annurev-med-042513-015127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042513-015127</ArticleId><ArticleId IdType="pubmed">25587647</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D.Y., Diéras V., Guardino E., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012;367:1783–1791. doi: 10.1056/NEJMoa1209124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1209124</ArticleId><ArticleId IdType="pmc">PMC5125250</ArticleId><ArticleId IdType="pubmed">23020162</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero P., Valmori D., Pittet M.J., Zippelius A., Rimoldi D., Lévy F., Dutoit V., Ayyoub M., Rubio-Godoy V., Michielin O., et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 2002;188:81–96. doi: 10.1034/j.1600-065X.2002.18808.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-065X.2002.18808.x</ArticleId><ArticleId IdType="pubmed">12445283</ArticleId></ArticleIdList></Reference><Reference><Citation>Khammari A., Labarrière N., Vignard V., Nguyen J.M., Pandolfino M.C., Knol A.C., Quéreux G., Saiagh S., Brocard A., Jotereau F., et al. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J. Investig. Dermatol. 2009;129:2835–2842. doi: 10.1038/jid.2009.144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2009.144</ArticleId><ArticleId IdType="pubmed">19554023</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Xu Y., Xiong W., Yin B., Huang Y., Chu J., Xing C., Qian C., Du Y., Duan T., et al. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. J. Immunother. Cancer. 2022;10:e004035. doi: 10.1136/jitc-2021-004035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-004035</ArticleId><ArticleId IdType="pmc">PMC8961179</ArticleId><ArticleId IdType="pubmed">35338087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K., Nishimura S., Ito T., Oka N., Kakinoki R., Akagi M. Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma. Eur. J. Histochem. 2022;66:3377. doi: 10.4081/ejh.2022.3377.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ejh.2022.3377</ArticleId><ArticleId IdType="pmc">PMC9046686</ArticleId><ArticleId IdType="pubmed">35448937</ArticleId></ArticleIdList></Reference><Reference><Citation>Freiberger S.N., Holzmann D., Morand G.B., Hüllner M., Levesque M.P., Dummer R., Koelzer V.H., Rupp N.J. Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients. J. Cancer Res. Clin. Oncol. 2023;149:5645–5653. doi: 10.1007/s00432-022-04514-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-022-04514-z</ArticleId><ArticleId IdType="pmc">PMC10356647</ArticleId><ArticleId IdType="pubmed">36527482</ArticleId></ArticleIdList></Reference><Reference><Citation>Turriziani M., Fantini M., Benvenuto M., Izzi V., Masuelli L., Sacchetti P., Modesti A., Bei R. Carcinoembryonic antigen (CEA)-based cancer vaccines: Recent patents and antitumor effects from experimental models to clinical trials. Recent. Pat. Anticancer Drug Discov. 2012;7:265–296. doi: 10.2174/157489212801820020.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157489212801820020</ArticleId><ArticleId IdType="pubmed">22630596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zbar A.P. The immunology of colorectal cancer. Surg. Oncol. 2004;13:45–53. doi: 10.1016/j.suronc.2004.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suronc.2004.09.010</ArticleId><ArticleId IdType="pubmed">15572086</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo-Merino J., Del-Toro-Arreola S., Rocha-Zavaleta L., Peralta-Zaragoza Ó., Jiménez-Lima R., Madrid-Marina V. Immunology of cervical cancer. Rev. Investig. Clin. 2020;72:188–197. doi: 10.24875/RIC.20000057.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/RIC.20000057</ArticleId><ArticleId IdType="pubmed">33064686</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X., Woodhouse I., Hancock G., Parker R., Marx K., Müller J., Salatino S., Partridge T., Nicastri A., Liao H., et al. Novel canonical and non-canonical viral antigens extend current targets for immunotherapy of HPV-driven cervical cancer. iScience. 2023;26:106101. doi: 10.1016/j.isci.2023.106101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.106101</ArticleId><ArticleId IdType="pmc">PMC9978627</ArticleId><ArticleId IdType="pubmed">36876126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbuya W., Held K., McHaro R.D., Haule A., Mhizde J., Mnkai J., Mahenge A., Mwakatima M., Sembo M., Mwalongo W., et al. Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living with HIV. Front. Immunol. 2021;12:742861. doi: 10.3389/fimmu.2021.742861.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.742861</ArticleId><ArticleId IdType="pmc">PMC8573218</ArticleId><ArticleId IdType="pubmed">34759925</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole A., Karuppiah V., Hartt A., Haidar J.N., Moureau S., Dobrzycki T., Hayes C., Rowley C., Dias J., Harper S., et al. Therapeutic high affinity T cell receptor targeting a KRAS(G12D) cancer neoantigen. Nat. Commun. 2022;13:5333. doi: 10.1038/s41467-022-32811-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32811-1</ArticleId><ArticleId IdType="pmc">PMC9464187</ArticleId><ArticleId IdType="pubmed">36088370</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidner R., Sanjuan Silva N., Huang H., Sprott D., Zheng C., Shih Y.P., Leung A., Payne R., Sutcliffe K., Cramer J., et al. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N. Engl. J. Med. 2022;386:2112–2119. doi: 10.1056/NEJMoa2119662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119662</ArticleId><ArticleId IdType="pmc">PMC9531755</ArticleId><ArticleId IdType="pubmed">35648703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q.J., Yu Z., Griffith K., Hanada K., Restifo N.P., Yang J.C. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol. Res. 2016;4:204–214. doi: 10.1158/2326-6066.CIR-15-0188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0188</ArticleId><ArticleId IdType="pmc">PMC4775432</ArticleId><ArticleId IdType="pubmed">26701267</ArticleId></ArticleIdList></Reference><Reference><Citation>Platten M., Bunse L., Wick A., Bunse T., Le Cornet L., Harting I., Sahm F., Sanghvi K., Tan C.L., Poschke I., et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021;592:463–468. doi: 10.1038/s41586-021-03363-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03363-z</ArticleId><ArticleId IdType="pmc">PMC8046668</ArticleId><ArticleId IdType="pubmed">33762734</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabit H., Nakada M., Furuta T., Watanabe T., Hayashi Y., Sato H., Kato Y., Hamada J. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence. Brain Tumor Pathol. 2014;31:242–246. doi: 10.1007/s10014-013-0172-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10014-013-0172-y</ArticleId><ArticleId IdType="pubmed">24384677</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields G.B., Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990;35:161–214. doi: 10.1111/j.1399-3011.1990.tb00939.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3011.1990.tb00939.x</ArticleId><ArticleId IdType="pubmed">2191922</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature. 2003;422:198–207. doi: 10.1038/nature01511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01511</ArticleId><ArticleId IdType="pubmed">12634793</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B. The perfect mix: Recent progress in adjuvant research. Nat. Rev. Microbiol. 2007;5:505–517. doi: 10.1038/nrmicro1681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1681</ArticleId><ArticleId IdType="pubmed">17558426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann M.F., Jennings G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010;10:787–796. doi: 10.1038/nri2868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2868</ArticleId><ArticleId IdType="pubmed">20948547</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: Developing the next generation of vaccines. Trends Immunol. 2006;27:573–579. doi: 10.1016/j.it.2006.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2006.10.005</ArticleId><ArticleId IdType="pubmed">17049307</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory A.E., Titball R., Williamson D. Vaccine delivery using nanoparticles. Front. Cell Infect. Microbiol. 2013;3:13. doi: 10.3389/fcimb.2013.00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2013.00013</ArticleId><ArticleId IdType="pmc">PMC3607064</ArticleId><ArticleId IdType="pubmed">23532930</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeway C.A., Jr., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002;20:197–216. doi: 10.1146/annurev.immunol.20.083001.084359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.20.083001.084359</ArticleId><ArticleId IdType="pubmed">11861602</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodcock J., Woosley R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 2008;59:1–12. doi: 10.1146/annurev.med.59.090506.155819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.med.59.090506.155819</ArticleId><ArticleId IdType="pubmed">18186700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaitin K.I. Deconstructing the drug development process: The new face of innovation. Clin. Pharmacol. Ther. 2010;87:356–361. doi: 10.1038/clpt.2009.293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2009.293</ArticleId><ArticleId IdType="pmc">PMC2953249</ArticleId><ArticleId IdType="pubmed">20130565</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. doi: 10.1038/32588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/32588</ArticleId><ArticleId IdType="pubmed">9521319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 1997;9:10–16. doi: 10.1016/S0952-7915(97)80153-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0952-7915(97)80153-7</ArticleId><ArticleId IdType="pubmed">9039784</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum J.S., Wearsch P.A., Cresswell P. Pathways of antigen processing. Annu. Rev. Immunol. 2013;31:443–473. doi: 10.1146/annurev-immunol-032712-095910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032712-095910</ArticleId><ArticleId IdType="pmc">PMC4026165</ArticleId><ArticleId IdType="pubmed">23298205</ArticleId></ArticleIdList></Reference><Reference><Citation>Joffre O.P., Segura E., Savina A., Amigorena S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 2012;12:557–569. doi: 10.1038/nri3254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3254</ArticleId><ArticleId IdType="pubmed">22790179</ArticleId></ArticleIdList></Reference><Reference><Citation>Neefjes J., Jongsma M.L., Paul P., Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 2011;11:823–836. doi: 10.1038/nri3084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3084</ArticleId><ArticleId IdType="pubmed">22076556</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellman I., Steinman R.M. Dendritic cells: Specialized and regulated antigen processing machines. Cell. 2001;106:255–258. doi: 10.1016/S0092-8674(01)00449-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(01)00449-4</ArticleId><ArticleId IdType="pubmed">11509172</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia K.C., Teyton L., Wilson I.A. Structural basis of T cell recognition. Annu. Rev. Immunol. 1999;17:369–397. doi: 10.1146/annurev.immunol.17.1.369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.17.1.369</ArticleId><ArticleId IdType="pubmed">10358763</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 2013;13:227–242. doi: 10.1038/nri3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3405</ArticleId><ArticleId IdType="pmc">PMC3786574</ArticleId><ArticleId IdType="pubmed">23470321</ArticleId></ArticleIdList></Reference><Reference><Citation>Harao M., Mittendorf E.A., Radvanyi L.G. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer. BioDrugs. 2015;29:15–30. doi: 10.1007/s40259-014-0114-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-014-0114-1</ArticleId><ArticleId IdType="pubmed">25523015</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh M.G., Tombácz I., Bettini E., Lederer K., Sittplangkoon C., Wilmore J.R., Gaudette B.T., Soliman O.Y., Pine M., Hicks P., et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54:2877–2892.e2877. doi: 10.1016/j.immuni.2021.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8566475</ArticleId><ArticleId IdType="pubmed">34852217</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiels J.P., van Baren N., Marchand M. Peptide-based cancer vaccines. Semin. Oncol. 2002;29:494–502. doi: 10.1053/sonc.2002.35244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/sonc.2002.35244</ArticleId><ArticleId IdType="pubmed">12407514</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannopoulos K., Dmoszynska A., Kowal M., Rolinski J., Gostick E., Price D.A., Greiner J., Rojewski M., Stilgenbauer S., Döhner H., et al. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia. 2010;24:798–805. doi: 10.1038/leu.2010.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2010.29</ArticleId><ArticleId IdType="pubmed">20220777</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumai T., Lee S., Cho H.I., Sultan H., Kobayashi H., Harabuchi Y., Celis E. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses. Cancer Immunol. Res. 2017;5:72–83. doi: 10.1158/2326-6066.CIR-16-0194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0194</ArticleId><ArticleId IdType="pmc">PMC5221568</ArticleId><ArticleId IdType="pubmed">27941004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagchi S., Yuan R., Engleman E.G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu. Rev. Pathol. 2021;16:223–249. doi: 10.1146/annurev-pathol-042020-042741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-042020-042741</ArticleId><ArticleId IdType="pubmed">33197221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartoglu U., Ames H. Ensuring quality and integrity of vaccines throughout the cold chain: The role of temperature monitoring. Expert. Rev. Vaccines. 2022;21:799–810. doi: 10.1080/14760584.2022.2061462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2061462</ArticleId><ArticleId IdType="pubmed">35373686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen D.D., Lorenson T., Bartholomew K., Villadiego S. Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries. Vaccine. 2016;34:899–904. doi: 10.1016/j.vaccine.2016.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.01.001</ArticleId><ArticleId IdType="pmc">PMC4744085</ArticleId><ArticleId IdType="pubmed">26778422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartoglu U., Milstien J. Tools and approaches to ensure quality of vaccines throughout the cold chain. Expert Rev. Vaccines. 2014;13:843–854. doi: 10.1586/14760584.2014.923761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2014.923761</ArticleId><ArticleId IdType="pmc">PMC4743593</ArticleId><ArticleId IdType="pubmed">24865112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd J., Lydon P., Ouhichi R., Zaffran M. Reducing the loss of vaccines from accidental freezing in the cold chain: The experience of continuous temperature monitoring in Tunisia. Vaccine. 2015;33:902–907. doi: 10.1016/j.vaccine.2014.10.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.10.080</ArticleId><ArticleId IdType="pmc">PMC4319682</ArticleId><ArticleId IdType="pubmed">25444810</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthias D.M., Robertson J., Garrison M.M., Newland S., Nelson C. Freezing temperatures in the vaccine cold chain: A systematic literature review. Vaccine. 2007;25:3980–3986. doi: 10.1016/j.vaccine.2007.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.02.052</ArticleId><ArticleId IdType="pubmed">17382434</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., Dyrhaug M., Trachsel S., Møller M., Eriksen J.A., et al. Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006;55:1553–1564. doi: 10.1007/s00262-006-0145-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-006-0145-7</ArticleId><ArticleId IdType="pmc">PMC11030882</ArticleId><ArticleId IdType="pubmed">16491401</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012;18:1254–1261. doi: 10.1038/nm.2883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2883</ArticleId><ArticleId IdType="pubmed">22842478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rini B.I., Stenzl A., Zdrojowy R., Kogan M., Shkolnik M., Oudard S., Weikert S., Bracarda S., Crabb S.J., Bedke J., et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1599–1611. doi: 10.1016/S1470-2045(16)30408-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(16)30408-9</ArticleId><ArticleId IdType="pubmed">27720136</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittendorf E.A., Clifton G.T., Holmes J.P., Clive K.S., Patil R., Benavides L.C., Gates J.D., Sears A.K., Stojadinovic A., Ponniah S., et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2012;118:2594–2602. doi: 10.1002/cncr.26574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.26574</ArticleId><ArticleId IdType="pmc">PMC3428069</ArticleId><ArticleId IdType="pubmed">21989902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittendorf E.A., Clifton G.T., Holmes J.P., Schneble E., van Echo D., Ponniah S., Peoples G.E. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann. Oncol. 2014;25:1735–1742. doi: 10.1093/annonc/mdu211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdu211</ArticleId><ArticleId IdType="pmc">PMC4143091</ArticleId><ArticleId IdType="pubmed">24907636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jäger E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jäger D., Arand M., Wada H., Noguchi Y., Stockert E., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 1998;187:265–270. doi: 10.1084/jem.187.2.265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.187.2.265</ArticleId><ArticleId IdType="pmc">PMC2212106</ArticleId><ArticleId IdType="pubmed">9432985</ArticleId></ArticleIdList></Reference><Reference><Citation>Odunsi K., Matsuzaki J., James S.R., Mhawech-Fauceglia P., Tsuji T., Miller A., Zhang W., Akers S.N., Griffiths E.A., Miliotto A., et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol. Res. 2014;2:37–49. doi: 10.1158/2326-6066.CIR-13-0126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0126</ArticleId><ArticleId IdType="pmc">PMC3925074</ArticleId><ArticleId IdType="pubmed">24535937</ArticleId></ArticleIdList></Reference><Reference><Citation>Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W., Lopez-Brea M., Vanakesa T., Jassem J., Kalofonos H., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J. Clin. Oncol. 2013;31:2396–2403. doi: 10.1200/JCO.2012.43.7103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2012.43.7103</ArticleId><ArticleId IdType="pubmed">23715567</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., Elisseeva O.A., Oji Y., Kawakami M., Ikegame K., et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA. 2004;101:13885–13890. doi: 10.1073/pnas.0405884101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0405884101</ArticleId><ArticleId IdType="pmc">PMC518848</ArticleId><ArticleId IdType="pubmed">15365188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.H., Cao Z., Farazuddin M., Chen J., Janczak K.W., Tang S., Cannon J., Baker J.R., Jr. A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation. Cancer Gene Ther. 2024;31:464–471. doi: 10.1038/s41417-023-00717-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-023-00717-9</ArticleId><ArticleId IdType="pubmed">38177307</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Che X., Wang X., Ma C., Wu G. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer. Pharmaceuticals. 2023;16:1384. doi: 10.3390/ph16101384.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16101384</ArticleId><ArticleId IdType="pmc">PMC10610367</ArticleId><ArticleId IdType="pubmed">37895855</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa V.M.L., Carvalho L. Heterogeneity in Lung Cancer. Pathobiology. 2018;85:96–107. doi: 10.1159/000487440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000487440</ArticleId><ArticleId IdType="pubmed">29635240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Ma Y., Liu F., Li B., Qiao D., Ren P., Wang M. Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment. Front. Immunol. 2023;14:1255799. doi: 10.3389/fimmu.2023.1255799.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1255799</ArticleId><ArticleId IdType="pmc">PMC10508181</ArticleId><ArticleId IdType="pubmed">37731507</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasyam N., Sharples K.J., Barrow C., Huang Y., Bauer E., Mester B., Wood C.E., Authier-Hall A., Dzhelali M., Ostapowicz T., et al. A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma. Cancer Immunol. Immunother. 2023;72:2267–2282. doi: 10.1007/s00262-023-03400-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-023-03400-y</ArticleId><ArticleId IdType="pmc">PMC10264280</ArticleId><ArticleId IdType="pubmed">36881133</ArticleId></ArticleIdList></Reference><Reference><Citation>Karanikas V., Hwang L.A., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H., Xing P.X., Jamieson G., Pietersz G., Tait B., et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Investig. 1997;100:2783–2792. doi: 10.1172/JCI119825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI119825</ArticleId><ArticleId IdType="pmc">PMC508483</ArticleId><ArticleId IdType="pubmed">9389743</ArticleId></ArticleIdList></Reference><Reference><Citation>Musselli C., Ragupathi G., Gilewski T., Panageas K.S., Spinat Y., Livingston P.O. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer. 2002;97:660–667. doi: 10.1002/ijc.10081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.10081</ArticleId><ArticleId IdType="pubmed">11807794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan R.K., Lee K.M., McKolanis J., Hitbold E., Schraut W., Moser A.J., Warnick E., Whiteside T., Osborne J., Kim H., et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 2005;54:254–264. doi: 10.1007/s00262-004-0581-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-004-0581-1</ArticleId><ArticleId IdType="pmc">PMC11034344</ArticleId><ArticleId IdType="pubmed">15372205</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayer J., Lancet J.E., Powers J., List A., Balducci L., Komrokji R., Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am. J. Hematol. 2015;90:602–607. doi: 10.1002/ajh.24014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.24014</ArticleId><ArticleId IdType="pmc">PMC4617516</ArticleId><ArticleId IdType="pubmed">25802083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zauderer M.G., Tsao A.S., Dao T., Panageas K., Lai W.V., Rimner A., Rusch V.W., Adusumilli P.S., Ginsberg M.S., Gomez D., et al. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clin. Cancer Res. 2017;23:7483–7489. doi: 10.1158/1078-0432.CCR-17-2169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-17-2169</ArticleId><ArticleId IdType="pmc">PMC5732877</ArticleId><ArticleId IdType="pubmed">28972039</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Shea A.E., Clifton G.T., Qiao N., Heckman-Stoddard B.M., Wojtowicz M., Dimond E., Bedrosian I., Weber D., Garber J.E., Husband A., et al. Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ. Cancer Prev. Res. 2023;16:333–341. doi: 10.1158/1940-6207.CAPR-22-0388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1940-6207.CAPR-22-0388</ArticleId><ArticleId IdType="pmc">PMC10903526</ArticleId><ArticleId IdType="pubmed">37259799</ArticleId></ArticleIdList></Reference><Reference><Citation>Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., Knutson K.L., Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 2002;20:2624–2632. doi: 10.1200/JCO.2002.06.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2002.06.171</ArticleId><ArticleId IdType="pubmed">12039923</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael M.G., Benavides L.C., Holmes J.P., Gates J.D., Mittendorf E.A., Ponniah S., Peoples G.E. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2010;116:292–301. doi: 10.1002/cncr.24756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.24756</ArticleId><ArticleId IdType="pubmed">19924797</ArticleId></ArticleIdList></Reference><Reference><Citation>François V., Ottaviani S., Renkvist N., Stockis J., Schuler G., Thielemans K., Colau D., Marchand M., Boon T., Lucas S., et al. The CD4+ T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res. 2009;69:4335–4345. doi: 10.1158/0008-5472.CAN-08-3726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-08-3726</ArticleId><ArticleId IdType="pubmed">19435913</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshita C., Takikawa M., Kume A., Miyata H., Ashizawa T., Iizuka A., Kiyohara Y., Yoshikawa S., Tanosaki R., Yamazaki N., et al. Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial. Oncol. Rep. 2012;28:1131–1138. doi: 10.3892/or.2012.1956.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2012.1956</ArticleId><ArticleId IdType="pmc">PMC3583475</ArticleId><ArticleId IdType="pubmed">22895835</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson J.H., Heimberger A.B., Archer G.E., Aldape K.D., Friedman A.H., Friedman H.S., Gilbert M.R., Herndon J.E., 2nd, McLendon R.E., Mitchell D.A., et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010;28:4722–4729. doi: 10.1200/jco.2010.28.6963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2010.28.6963</ArticleId><ArticleId IdType="pmc">PMC3020702</ArticleId><ArticleId IdType="pubmed">20921459</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller M., Butowski N., Tran D.D., Recht L.D., Lim M., Hirte H., Ashby L., Mechtler L., Goldlust S.A., Iwamoto F., et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373–1385. doi: 10.1016/S1470-2045(17)30517-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(17)30517-X</ArticleId><ArticleId IdType="pubmed">28844499</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton G., Silcocks P., Cox T., Valle J., Wadsley J., Propper D., Coxon F., Ross P., Madhusudan S., Roques T., et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15:829–840. doi: 10.1016/S1470-2045(14)70236-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70236-0</ArticleId><ArticleId IdType="pubmed">24954781</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher T., Bunse L., Pusch S., Sahm F., Wiestler B., Quandt J., Menn O., Osswald M., Oezen I., Ott M., et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512:324–327. doi: 10.1038/nature13387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13387</ArticleId><ArticleId IdType="pubmed">25043048</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenstermaker R.A., Ciesielski M.J., Qiu J., Yang N., Frank C.L., Lee K.P., Mechtler L.R., Belal A., Ahluwalia M.S., Hutson A.D. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol. Immunother. 2016;65:1339–1352. doi: 10.1007/s00262-016-1890-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-016-1890-x</ArticleId><ArticleId IdType="pmc">PMC5069322</ArticleId><ArticleId IdType="pubmed">27576783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia M.S., Reardon D.A., Abad A.P., Curry W.T., Wong E.T., Figel S.A., Mechtler L.L., Peereboom D.M., Hutson A.D., Withers H.G., et al. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J. Clin. Oncol. 2023;41:1453–1465. doi: 10.1200/JCO.22.00996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.00996</ArticleId><ArticleId IdType="pmc">PMC9995096</ArticleId><ArticleId IdType="pubmed">36521103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Ma J.A., Zhang H.X., Jiang Y.N., Luo W.H. Cancer vaccines: Targeting KRAS-driven cancers. Expert Rev. Vaccines. 2020;19:163–173. doi: 10.1080/14760584.2020.1733420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2020.1733420</ArticleId><ArticleId IdType="pubmed">32174221</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale P., Botta C., Staropoli N., Nardone V., Pastina P., Ulivieri C., Gandolfo C., Baldari T.C., Lazzi S., Ciliberto D., et al. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. Oncotarget. 2018;9:20539–20554. doi: 10.18632/oncotarget.24993.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.24993</ArticleId><ArticleId IdType="pmc">PMC5945541</ArticleId><ArticleId IdType="pubmed">29755670</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjertsen M.K., Buanes T., Rosseland A.R., Bakka A., Gladhaug I., Søreide O., Eriksen J.A., Møller M., Baksaas I., Lothe R.A., et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer. 2001;92:441–450. doi: 10.1002/ijc.1205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.1205</ArticleId><ArticleId IdType="pubmed">11291084</ArticleId></ArticleIdList></Reference><Reference><Citation>Postow M.A., Callahan M.K., Wolchok J.D. Immune Checkpoint Blockade in Cancer Therapy. J. Clin. Oncol. 2015;33:1974–1982. doi: 10.1200/JCO.2014.59.4358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.59.4358</ArticleId><ArticleId IdType="pmc">PMC4980573</ArticleId><ArticleId IdType="pubmed">25605845</ArticleId></ArticleIdList></Reference><Reference><Citation>Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 1999;5:1289–1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">10389911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363:711–723. doi: 10.1056/NEJMoa1003466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId><ArticleId IdType="pmc">PMC3549297</ArticleId><ArticleId IdType="pubmed">20525992</ArticleId></ArticleIdList></Reference><Reference><Citation>Motz G.T., Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61–73. doi: 10.1016/j.immuni.2013.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.07.005</ArticleId><ArticleId IdType="pmc">PMC3782392</ArticleId><ArticleId IdType="pubmed">23890064</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxevanis C.N., Perez S.A., Papamichail M. Cancer immunotherapy. Crit. Rev. Clin. Lab. Sci. 2009;46:167–189. doi: 10.1080/10408360902937809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408360902937809</ArticleId><ArticleId IdType="pubmed">19650714</ArticleId></ArticleIdList></Reference><Reference><Citation>Demaria S., Formenti S.C. Role of T lymphocytes in tumor response to radiotherapy. Front. Oncol. 2012;2:95. doi: 10.3389/fonc.2012.00095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2012.00095</ArticleId><ArticleId IdType="pmc">PMC3426850</ArticleId><ArticleId IdType="pubmed">22937524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kepp O., Galluzzi L., Martins I., Schlemmer F., Adjemian S., Michaud M., Sukkurwala A.Q., Menger L., Zitvogel L., Kroemer G. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30:61–69. doi: 10.1007/s10555-011-9273-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-011-9273-4</ArticleId><ArticleId IdType="pubmed">21249425</ArticleId></ArticleIdList></Reference><Reference><Citation>Slingluff C.L., Jr., Petroni G.R., Chianese-Bullock K.A., Smolkin M.E., Ross M.I., Haas N.B., von Mehren M., Grosh W.W. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J. Clin. Oncol. 2011;29:2924–2932. doi: 10.1200/JCO.2010.33.8053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.33.8053</ArticleId><ArticleId IdType="pmc">PMC3138719</ArticleId><ArticleId IdType="pubmed">21690475</ArticleId></ArticleIdList></Reference><Reference><Citation>Iinuma H., Fukushima R., Inaba T., Tamura J., Inoue T., Ogawa E., Horikawa M., Ikeda Y., Matsutani N., Takeda K., et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J. Transl. Med. 2014;12:84. doi: 10.1186/1479-5876-12-84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-12-84</ArticleId><ArticleId IdType="pmc">PMC4234129</ArticleId><ArticleId IdType="pubmed">24708624</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel J.A., Otsuka A., Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front. Oncol. 2018;8:86. doi: 10.3389/fonc.2018.00086.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00086</ArticleId><ArticleId IdType="pmc">PMC5883082</ArticleId><ArticleId IdType="pubmed">29644214</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi Y., Sasada T. Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. J. Immunol. Res. 2020;2020:5825401. doi: 10.1155/2020/5825401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5825401</ArticleId><ArticleId IdType="pmc">PMC7685825</ArticleId><ArticleId IdType="pubmed">33282961</ArticleId></ArticleIdList></Reference><Reference><Citation>Trac N.T., Chung E.J. Peptide-based targeting of immunosuppressive cells in cancer. Bioact. Mater. 2020;5:92–101. doi: 10.1016/j.bioactmat.2020.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2020.01.006</ArticleId><ArticleId IdType="pmc">PMC6962647</ArticleId><ArticleId IdType="pubmed">31956738</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff A.L., Longway G., Mitchell J.T., Andaloori L., Davis-Marcisak E., Chen F., Lyman M.R., Wang R., Mathew J., Barrett B., et al. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight. 2023;8:e174027. doi: 10.1172/jci.insight.174027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.174027</ArticleId><ArticleId IdType="pmc">PMC10795827</ArticleId><ArticleId IdType="pubmed">38063199</ArticleId></ArticleIdList></Reference><Reference><Citation>Massarelli E., William W., Johnson F., Kies M., Ferrarotto R., Guo M., Feng L., Lee J.J., Tran H., Kim Y.U., et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5:67–73. doi: 10.1001/jamaoncol.2018.4051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2018.4051</ArticleId><ArticleId IdType="pmc">PMC6439768</ArticleId><ArticleId IdType="pubmed">30267032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y., Okazaki T., Tanaka Y., Murahashi M., Yamada Y., Yamada K., Takahashi A., Inoue H., Kishimoto J., Nakanishi Y., et al. A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS ONE. 2018;13:e0187878. doi: 10.1371/journal.pone.0187878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0187878</ArticleId><ArticleId IdType="pmc">PMC5749706</ArticleId><ArticleId IdType="pubmed">29293510</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirahama T., Muroya D., Matsueda S., Yamada A., Shichijo S., Naito M., Yamashita T., Sakamoto S., Okuda K., Itoh K., et al. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. Cancer Sci. 2017;108:838–845. doi: 10.1111/cas.13193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13193</ArticleId><ArticleId IdType="pmc">PMC5448649</ArticleId><ArticleId IdType="pubmed">28188670</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J., Wang L.F., Zou Z.Y., Kong W.W., Yan J., Meng F.Y., Chen F.J., Du J., Shao J., Xu Q.P., et al. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J. Gastroenterol. 2017;23:5395–5404. doi: 10.3748/wjg.v23.i29.5395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i29.5395</ArticleId><ArticleId IdType="pmc">PMC5550789</ArticleId><ArticleId IdType="pubmed">28839440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013;31:51–72. doi: 10.1146/annurev-immunol-032712-100008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032712-100008</ArticleId><ArticleId IdType="pubmed">23157435</ArticleId></ArticleIdList></Reference><Reference><Citation>Melero I., Berman D.M., Aznar M.A., Korman A.J., Pérez Gracia J.L., Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer. 2015;15:457–472. doi: 10.1038/nrc3973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3973</ArticleId><ArticleId IdType="pubmed">26205340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L., Apetoh L., Ghiringhelli F., André F., Tesniere A., Kroemer G. The anticancer immune response: Indispensable for therapeutic success? J. Clin. Investig. 2008;118:1991–2001. doi: 10.1172/JCI35180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI35180</ArticleId><ArticleId IdType="pmc">PMC2396905</ArticleId><ArticleId IdType="pubmed">18523649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L., Galluzzi L., Smyth M.J., Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance. Immunity. 2013;39:74–88. doi: 10.1016/j.immuni.2013.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.06.014</ArticleId><ArticleId IdType="pubmed">23890065</ArticleId></ArticleIdList></Reference><Reference><Citation>Preet Kaur A., Alice A., Crittenden M.R., Gough M.J. The role of dendritic cells in radiation-induced immune responses. Int. Rev. Cell Mol. Biol. 2023;378:61–104. doi: 10.1016/bs.ircmb.2023.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ircmb.2023.02.002</ArticleId><ArticleId IdType="pubmed">37438021</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura S., Wang B., Kawashima N., Braunstein S., Badura M., Cameron T.O., Babb J.S., Schneider R.J., Formenti S.C., Dustin M.L., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 2008;181:3099–3107. doi: 10.4049/jimmunol.181.5.3099.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.5.3099</ArticleId><ArticleId IdType="pmc">PMC2587101</ArticleId><ArticleId IdType="pubmed">18713980</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaue D., McBride W.H. T lymphocytes and normal tissue responses to radiation. Front. Oncol. 2012;2:119. doi: 10.3389/fonc.2012.00119.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2012.00119</ArticleId><ArticleId IdType="pmc">PMC3445965</ArticleId><ArticleId IdType="pubmed">23050243</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnett C.T., Palena C., Chakraborty M., Tsang K.Y., Schlom J., Hodge J.W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985–7994. doi: 10.1158/0008-5472.CAN-04-1525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-04-1525</ArticleId><ArticleId IdType="pubmed">15520206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F., Lanzavecchia A., Araki K., Ahmed R. From vaccines to memory and back. Immunity. 2010;33:451–463. doi: 10.1016/j.immuni.2010.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC3760154</ArticleId><ArticleId IdType="pubmed">21029957</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulley J.L., Arlen P.M., Madan R.A., Tsang K.Y., Pazdur M.P., Skarupa L., Jones J.L., Poole D.J., Higgins J.P., Hodge J.W., et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 2010;59:663–674. doi: 10.1007/s00262-009-0782-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-009-0782-8</ArticleId><ArticleId IdType="pmc">PMC2832083</ArticleId><ArticleId IdType="pubmed">19890632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Cladel N., Balogh K., Christensen N. Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits. Vaccine. 2010;28:3706–3713. doi: 10.1016/j.vaccine.2010.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.015</ArticleId><ArticleId IdType="pmc">PMC2879011</ArticleId><ArticleId IdType="pubmed">20332046</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Mariscal L., Posadas Y., Miranda J., Uc P.Y., Ortega-Olvera J.M., Hernández S. Strategies that Target Tight Junctions for Enhanced Drug Delivery. Curr. Pharm. Des. 2016;22:5313–5346. doi: 10.2174/1381612822666160720163656.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612822666160720163656</ArticleId><ArticleId IdType="pubmed">27510485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Zhu L., Li Y., Zhang X., Xu S., Yang G., Delair T. Chitosan-based Colloidal Polyelectrolyte Complexes for Drug Delivery: A Review. Carbohydr. Polym. 2020;238:116126. doi: 10.1016/j.carbpol.2020.116126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2020.116126</ArticleId><ArticleId IdType="pubmed">32299572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolhassani A., Safaiyan S., Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer. 2011;10:3. doi: 10.1186/1476-4598-10-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-10-3</ArticleId><ArticleId IdType="pmc">PMC3024302</ArticleId><ArticleId IdType="pubmed">21211062</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S., Goand U.K., Husain A., Katekar R.A., Garg R., Gayen J.R. Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability. Drug Dev. Res. 2021;82:927–944. doi: 10.1002/ddr.21832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21832</ArticleId><ArticleId IdType="pubmed">33988872</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Li M., Du G., Chen X., Sun X. Advancedoral vaccine delivery strategies for improving the immunity. Adv. Drug Deliv. Rev. 2021;177:113928. doi: 10.1016/j.addr.2021.113928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.113928</ArticleId><ArticleId IdType="pubmed">34411689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunisawa J., Kurashima Y., Kiyono H. Gut-associated lymphoid tissues for the development of oral vaccines. Adv. Drug Deliv. Rev. 2012;64:523–530. doi: 10.1016/j.addr.2011.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2011.07.003</ArticleId><ArticleId IdType="pubmed">21827802</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshweiat A., Ambrus R., Csoka I. Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery. Curr. Med. Chem. 2019;26:6459–6492. doi: 10.2174/0929867326666190827151741.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867326666190827151741</ArticleId><ArticleId IdType="pubmed">31453778</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Yang G., Schluns K.S., Anthony S.M., Sastry K.J. Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge. PLoS ONE. 2014;9:e90001. doi: 10.1371/journal.pone.0090001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090001</ArticleId><ArticleId IdType="pmc">PMC3943861</ArticleId><ArticleId IdType="pubmed">24599269</ArticleId></ArticleIdList></Reference><Reference><Citation>Disis M.L. Immune regulation of cancer. J. Clin. Oncol. 2010;28:4531–4538. doi: 10.1200/JCO.2009.27.2146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.27.2146</ArticleId><ArticleId IdType="pmc">PMC3041789</ArticleId><ArticleId IdType="pubmed">20516428</ArticleId></ArticleIdList></Reference><Reference><Citation>Daiko H., Marafioti T., Fujiwara T., Shirakawa Y., Nakatsura T., Kato K., Puccio I., Hikichi T., Yoshimura S., Nakagawa T., et al. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Cancer Immunol. Immunother. 2020;69:2247–2257. doi: 10.1007/s00262-020-02619-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-020-02619-3</ArticleId><ArticleId IdType="pmc">PMC7568713</ArticleId><ArticleId IdType="pubmed">32500232</ArticleId></ArticleIdList></Reference><Reference><Citation>Slingluff C.L., Jr., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., Patterson J.W., Deacon D.H., Hibbitts S., Teates D., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 2003;21:4016–4026. doi: 10.1200/JCO.2003.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2003.10.005</ArticleId><ArticleId IdType="pubmed">14581425</ArticleId></ArticleIdList></Reference><Reference><Citation>Disis M.L., Wallace D.R., Gooley T.A., Dang Y., Slota M., Lu H., Coveler A.L., Childs J.S., Higgins D.M., Fintak P.A., et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 2009;27:4685–4692. doi: 10.1200/JCO.2008.20.6789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.20.6789</ArticleId><ArticleId IdType="pmc">PMC2754913</ArticleId><ArticleId IdType="pubmed">19720923</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara Y., Okada K., Omori T., Sugimura K., Miyata H., Ohue M., Kobayashi S., Takahashi H., Nakano H., Mochizuki C., et al. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int. J. Oncol. 2017;50:1655–1662. doi: 10.3892/ijo.2017.3955.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2017.3955</ArticleId><ArticleId IdType="pubmed">28393243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara M., Nishida Y., Kitano S., Kawai A., Muraoka D., Momose F., Harada N., Miyahara Y., Seo N., Hattori H., et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. Int. J. Cancer. 2023;152:2554–2566. doi: 10.1002/ijc.34453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.34453</ArticleId><ArticleId IdType="pubmed">36727538</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada A., Inoue M., Kondo O., Yamada-Nakata K., Ishihara T., Kuwae Y., Nishikawa M., Ammori Y., Tsuboi A., Oji Y., et al. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children. Pediatr. Blood Cancer. 2016;63:234–241. doi: 10.1002/pbc.25792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.25792</ArticleId><ArticleId IdType="pubmed">26469989</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009;9:287–293. doi: 10.1038/nri2510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2510</ArticleId><ArticleId IdType="pmc">PMC3147301</ArticleId><ArticleId IdType="pubmed">19247370</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieg A.M. Development of TLR9 agonists for cancer therapy. J. Clin. Investig. 2007;117:1184–1194. doi: 10.1172/JCI31414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI31414</ArticleId><ArticleId IdType="pmc">PMC1857270</ArticleId><ArticleId IdType="pubmed">17476348</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat. Med. 2013;19:1597–1608. doi: 10.1038/nm.3409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3409</ArticleId><ArticleId IdType="pubmed">24309663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani P., Teymouri M., Nikpoor A.R., Navashenaq J.G., Gholizadeh Z., Darban S.A., Jaafari M.R. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer. Eur. J. Cancer. 2020;129:80–96. doi: 10.1016/j.ejca.2020.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2020.01.010</ArticleId><ArticleId IdType="pubmed">32145473</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzpodien J., Fluck M., Reitz M. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients. Cancer Biother. Radiopharm. 2004;19:758–763. doi: 10.1089/cbr.2004.19.758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cbr.2004.19.758</ArticleId><ArticleId IdType="pubmed">15665624</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield L.H., Zhao F., Lee S., Tarhini A.A., Margolin K.A., White R.L., Atkins M.B., Cohen G.I., Whiteside T.L., Kirkwood J.M., et al. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697) Clin. Cancer Res. 2017;23:5034–5043. doi: 10.1158/1078-0432.CCR-16-3016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-3016</ArticleId><ArticleId IdType="pmc">PMC5581724</ArticleId><ArticleId IdType="pubmed">28536308</ArticleId></ArticleIdList></Reference><Reference><Citation>Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene. 2003;22:3188–3192. doi: 10.1038/sj.onc.1206459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1206459</ArticleId><ArticleId IdType="pubmed">12789295</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B.Z., Ye Q.L., Xu W.D., Li J.H., Ye D.Q., Xu Y. GM-CSF alters dendritic cells in autoimmune diseases. Autoimmunity. 2013;46:409–418. doi: 10.3109/08916934.2013.803533.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2013.803533</ArticleId><ArticleId IdType="pubmed">23786272</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K.E., Fritzell S., Badn W., Eberstål S., Janelidze S., Visse E., Darabi A., Siesjö P. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells. Int. J. Cancer. 2009;124:630–637. doi: 10.1002/ijc.23986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.23986</ArticleId><ArticleId IdType="pubmed">18972433</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H.Y., Li N., Yao N., Xu X.F., Wang H.X., Liu X.Y., Zhang Y. CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM-CSF and IL-12, enhance the anti-renal cortical adenocarcinoma effect. Oncol. Rep. 2019;42:866–879. doi: 10.3892/or.2019.7208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2019.7208</ArticleId><ArticleId IdType="pubmed">31233203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007;13:552–559. doi: 10.1038/nm1589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1589</ArticleId><ArticleId IdType="pubmed">17479101</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002;20:709–760. doi: 10.1146/annurev.immunol.20.100301.064842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.20.100301.064842</ArticleId><ArticleId IdType="pubmed">11861616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirota H., Klinman D.M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert. Rev. Vaccines. 2014;13:299–312. doi: 10.1586/14760584.2014.863715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2014.863715</ArticleId><ArticleId IdType="pmc">PMC6335645</ArticleId><ArticleId IdType="pubmed">24308579</ArticleId></ArticleIdList></Reference><Reference><Citation>Speiser D.E., Liénard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Investig. 2005;115:739–746. doi: 10.1172/JCI23373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI23373</ArticleId><ArticleId IdType="pmc">PMC546459</ArticleId><ArticleId IdType="pubmed">15696196</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomann J.S., Heurtault B., Weidner S., Brayé M., Beyrath J., Fournel S., Schuber F., Frisch B. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials. 2011;32:4574–4583. doi: 10.1016/j.biomaterials.2011.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2011.03.015</ArticleId><ArticleId IdType="pubmed">21474175</ArticleId></ArticleIdList></Reference><Reference><Citation>HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine. 2002;20((Suppl. S3)):S34–S39. doi: 10.1016/S0264-410X(02)00169-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(02)00169-X</ArticleId><ArticleId IdType="pubmed">12184362</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59—An innately attractive adjuvant formulation. Vaccine. 2012;30:4341–4348. doi: 10.1016/j.vaccine.2011.09.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.09.061</ArticleId><ArticleId IdType="pubmed">22682289</ArticleId></ArticleIdList></Reference><Reference><Citation>Garçon N., Di Pasquale A. From discovery to licensure, the Adjuvant System story. Hum. Vaccin. Immunother. 2017;13:19–33. doi: 10.1080/21645515.2016.1225635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1225635</ArticleId><ArticleId IdType="pmc">PMC5287309</ArticleId><ArticleId IdType="pubmed">27636098</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006;5:471–484. doi: 10.1038/nrd2059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2059</ArticleId><ArticleId IdType="pubmed">16763660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kensil C.R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996;13:1–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">8853958</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004;4:499–511. doi: 10.1038/nri1391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1391</ArticleId><ArticleId IdType="pubmed">15229469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu X., Xiang D. Nanoparticle drug delivery systems: An excellent carrier for tumor peptide vaccines. Drug Deliv. 2018;25:1319–1327. doi: 10.1080/10717544.2018.1477857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10717544.2018.1477857</ArticleId><ArticleId IdType="pmc">PMC6058474</ArticleId><ArticleId IdType="pubmed">29869539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozako T., Arima N., Yoshimitsu M., Honda S.I., Soeda S. Liposomes and nanotechnology in drug development: Focus on oncotargets. Int. J. Nanomed. 2012;7:4943–4951. doi: 10.2147/IJN.S30726.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S30726</ArticleId><ArticleId IdType="pmc">PMC3446859</ArticleId><ArticleId IdType="pubmed">23028222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Liu H., Ye Y., Lei Y., Islam R., Tan S., Tong R., Miao Y.B., Cai L. Smart nanoparticles for cancer therapy. Signal Transduct. Target. Ther. 2023;8:418. doi: 10.1038/s41392-023-01642-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01642-x</ArticleId><ArticleId IdType="pmc">PMC10622502</ArticleId><ArticleId IdType="pubmed">37919282</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Z., Sun Y., Xiao H., Li P., Liu M., Ding F., Kan W., Miao R. Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle. Biomed. Pharmacother. 2017;85:160–168. doi: 10.1016/j.biopha.2016.11.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2016.11.132</ArticleId><ArticleId IdType="pubmed">27930982</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis J., Katti P., Martin A.M., Hills T., Seymour L.W., Shenton D.P., Carlisle R.C. A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response. Eur. J. Pharm. Sci. 2020;152:105456. doi: 10.1016/j.ejps.2020.105456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2020.105456</ArticleId><ArticleId IdType="pubmed">32653563</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia F., Liu X., Li L., Mallapragada S., Narasimhan B., Wang Q. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J. Control Release. 2013;172:1020–1034. doi: 10.1016/j.jconrel.2013.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2013.10.012</ArticleId><ArticleId IdType="pubmed">24140748</ArticleId></ArticleIdList></Reference><Reference><Citation>Frézard F. Liposomes: From biophysics to the design of peptide vaccines. Braz. J. Med. Biol. Res. 1999;32:181–189. doi: 10.1590/S0100-879X1999000200006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0100-879X1999000200006</ArticleId><ArticleId IdType="pubmed">10347753</ArticleId></ArticleIdList></Reference><Reference><Citation>Boks M.A., Bruijns S.C.M., Ambrosini M., Kalay H., van Bloois L., Storm G., Gruijl T., van Kooyk Y. In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells. J. Investig. Dermatol. 2015;135:2697–2704. doi: 10.1038/jid.2015.226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2015.226</ArticleId><ArticleId IdType="pubmed">26083554</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Li W., Kirberger M., Liao W., Ren J. Design of nanomaterial based systems for novel vaccine development. Biomater. Sci. 2016;4:785–802. doi: 10.1039/C5BM00507H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5BM00507H</ArticleId><ArticleId IdType="pubmed">26891972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanjale M.V., Kumar G.S.V. Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma. Expert. Opin. Drug Deliv. 2017;14:811–824. doi: 10.1080/17425247.2017.1242574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2017.1242574</ArticleId><ArticleId IdType="pubmed">27690671</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv S., Song K., Yen A., Peeler D.J., Nguyen D.C., Olshefsky A., Sylvestre M., Srinivasan S., Stayton P.S., Pun S.H. Well-Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity. Adv. Healthc. Mater. 2022;11:e2101651. doi: 10.1002/adhm.202101651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202101651</ArticleId><ArticleId IdType="pmc">PMC9043035</ArticleId><ArticleId IdType="pubmed">34706166</ArticleId></ArticleIdList></Reference><Reference><Citation>Song K., Nguyen D.C., Luu T., Yazdani O., Roy D., Stayton P.S., Pun S.H. A mannosylated polymer with endosomal release properties for peptide antigen delivery. J. Control Release. 2023;356:232–241. doi: 10.1016/j.jconrel.2023.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2023.03.004</ArticleId><ArticleId IdType="pmc">PMC10693254</ArticleId><ArticleId IdType="pubmed">36878319</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X. Gold Nanoparticles: Recent Advances in the Biomedical Applications. Cell Biochem. Biophys. 2015;72:771–775. doi: 10.1007/s12013-015-0529-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12013-015-0529-4</ArticleId><ArticleId IdType="pubmed">25663504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey A.K., Gonon A., Pécheur E.I., Pezet M., Villiers C., Marche P.N. Impact of Gold Nanoparticles on the Functions of Macrophages and Dendritic Cells. Cells. 2021;10:96. doi: 10.3390/cells10010096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010096</ArticleId><ArticleId IdType="pmc">PMC7826823</ArticleId><ArticleId IdType="pubmed">33430453</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M., Li J., Gu P., Fan X. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Bioact. Mater. 2021;6:1973–1987. doi: 10.1016/j.bioactmat.2020.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2020.12.010</ArticleId><ArticleId IdType="pmc">PMC7773537</ArticleId><ArticleId IdType="pubmed">33426371</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida J.P.M., Lin A.Y., Figueroa E.R., Foster A.E., Drezek R.A. In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. Small. 2015;11:1453–1459. doi: 10.1002/smll.201402179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.201402179</ArticleId><ArticleId IdType="pmc">PMC4373976</ArticleId><ArticleId IdType="pubmed">25354691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>